NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
55 hedge funds and large institutions have $166M invested in NKGen Biotech, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 10 closing their positions.
4% more capital invested
Capital invested by funds: $159M → $166M (+$7.1M)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
8% less funds holding
Funds holding: 60 → 55 (-5)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$8.14M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.6M |
| 3 |
KL
KIM LLC
Wichita,
Kansas
|
+$3.03M |
| 4 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$2.95M |
| 5 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$5.87M |
| 2 |
CAC
Cowen and Company
New York
|
-$3.62M |
| 3 |
TCA
Taconic Capital Advisors
New York
|
-$3.48M |
| 4 |
JP Morgan Chase
New York
|
-$2.37M |
| 5 |
EC
Elequin Capital
New York
|
-$2.18M |
NKGN Hedge Fund Activity: Q1 2023 in Review
55 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2023, worth a combined $166M — up 4.5% from $159M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NKGN and 6 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $8.14M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.87M sold.
- 55 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2023, down from 60 in Q4 2022.
- Funds reported $166M of NKGen Biotech, Inc. Common Stock stock for Q1 2023, up 4.5% quarter-over-quarter.
- 6 funds opened new NKGen Biotech, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -4 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2023 was Aristeia Capital, an estimated $8.14M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q1 2023 was Marshall Wace, an estimated $5.87M sold.
Based on aggregated 13F filings for Q1 2023.